Recent trends in selective serotonin reuptake inhibitor use in pregnancy

Journal of Clinical Psychopharmacology

Volumn 28, Issue 6, 2008, Pages 714-716

  Wichman, Christina L ^a   Fothergill, Amy ^b   Moore, Katherine M ^a   Lang, Tara R ^a   Heise, Robert H ^a   Watson, William J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ANTIDEPRESSANT AGENT;

DELIVERY; DEPRESSION; DRUG EXPOSURE; FEMALE; FETUS RISK; FOOD AND DRUG ADMINISTRATION; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PREGNANCY; PREGNANT WOMAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; UNITED STATES; CLINICAL PRACTICE; DRUG EFFECT; DRUG USE; FETUS; PREGNANCY COMPLICATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME;

ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG UTILIZATION REVIEW; FEMALE; FETUS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PREGNANCY COMPLICATIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 59049083592     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31818b53fd     Document Type: Letter

References (16)

1. Burt VK, Hendrick VC. Clinical Manual of Women's Mental Health. Washington, DC: American Psychiatric Publishing, Inc; 2005.
2. Kornstein SG, Clayton AH. Women's Mental Health. A Comprehensive Textbook.New York, NY: Guilford Press; 2002.
3. Alwan S, Reefhuis J, Rasmussen SA, et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. NEJM. 2007;356:2684-2692.
4. Bar-Oz B, Einarson T, Einarson A, et al. Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clin Ther. 2007;29: 918-926.
5. Berard A, Ramos E, Rey E, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol. 2006;80:18-27.
6. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. NEJM. 1996;335:1010-1015.
7. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. NEJM. 2006;354: 579-587.
8. Louik C, Lin AE, Werler MM, et al. First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. NEJM. 2007;356:2675-2683.
9. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol. 2005; 106:1289-1296.
10. Oberlander T, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry. 2006;63:898-906.
11. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first- trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248.
12. Sanz EJ, De-las-Cuevas C, Kiuru A, et al. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365: 482-487.
13. Food and Drug Administration. FDA public health advisory: paroxetine [electronic citation]. Available at: http://www.fda.gov/cder/drug/advisory/ paroxetine200512.htm. Accessed December 17, 2007.
14. Mills JL. Depressing observations on the use of selective serotonin-reuptake inhibitors during pregnancy. NEJM. 2006;354: 636-638.
15. Andrade S, Gurwitz J, Davis R, et al. Prescriptiondruguse in pregnancy.Am J Obstet Gynecol. 2004;191:398-407.
16. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol. 2007;196: 544e-544e5.